N6- 腺苷酸甲基化与铁死亡在慢性肝损伤中的研究进展

梅 玉(内蒙古民族大学临床医学院，中国;)
志强 韩(内蒙古民族大学附属医院药物临床试验机构办公室，中国;)

摘要

慢性肝损伤是全世界范围内普遍存在的一种肝脏疾病，有复杂的发病机制，内容涉及到多种细胞信号通路和生物化学过程，给临床治疗带来了挑战。慢性肝损伤是多因素参与的复杂病理过程，在其发生和发展中，N6-腺苷酸甲基化（N6-methyladenosine, m6A）和铁死亡（ferroptosis）通过基因表达和细胞死亡途径，发挥关键的分子调控作用。m6A通过影响RNA转录和翻译过程，对肝细胞的生理功能产生深远影响，而铁死亡则是涉及铁离子与脂质过氧化的相互作用的一种新型的细胞死亡方式。实验数据表明，m6A除参与调节肝细胞的损伤及再生过程外，同时参与铁死亡过程，为理解慢性肝损伤的病理机制提供了新的视角。深入探讨铁死亡与m6A的关系，可为慢性肝损伤的治疗开辟新思路和靶点。

关键词

N6-腺苷酸甲基化；铁死亡；慢性肝损伤；机制研究

参考

Horn P, Tacke F. Metabolic reprogramming in liver fibrosis[J]. Cell Metab, 2024,36(7):1439-1455.

Devarbhavi H, Asrani S K, Arab J P, et al. Global burden of liver disease: 2023 update[J]. J Hepatol, 2023,79(2):516-537.

Ming X, Chen S, Li H, et al. m6A RNA Methylation and Implications for Hepatic Lipid Metabolism[J]. DNA Cell Biol, 2024,43(6):271-278.

胡杨, 郭志国. m6A修饰在肝癌中的调控作用研究进展[J]. 现代消化及介入诊疗, 2023,28(12):1583-1587.

Zhu L, Luo S, Zhu Y, et al. The Emerging Role of Ferroptosis in Various Chronic Liver Diseases: Opportunity or Challenge[J]. J Inflamm Res, 2023,16:381-389.

李欣, 陶亮, 钟美娟, 等. 铁死亡参与肝疾病研究进展[J]. 浙江大学学报(医学版), 2024,53(06):747-755.

Du K, Oh S H, Dutta R K, et al. Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells but exacerbates chronic liver injury[J]. Liver Int, 2021,41(9):2214-2227.

Shen M, Li Y, Wang Y, et al. N(6)-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells[J]. Redox Biol, 2021,47:102151.

Xiao J, Wang F, Wong N K, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019,71(1):212-221.

Ramadan H K, Badr G, Ramadan N K, et al. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study[J]. Pathog Dis, 2021,79(3).

杨星, 王振, 李淑娣, 等. 基于PI3K/Akt信号通路探讨中药活性成分抗肝纤维化的研究现状[J]. 中国实验方剂学杂志, 2023,29(13):230-240.

Bernard J K, Marakovits C, Smith L G, et al. Mast Cell and Innate Immune Cell Communication in Cholestatic Liver Disease[J]. Semin Liver Dis, 2023,43(2):226-233.

Allameh A, Niayesh-Mehr R, Aliarab A, et al. Oxidative Stress in Liver Pathophysiology and Disease[J]. Antioxidants (Basel), 2023,12(9).

刘玲玲, 张鲁宁, 姜胜男, 等. 基于Keap1/Nrf2/ARE信号通路探讨丹皮酚改善酒精性肝、脑损伤小鼠氧化应激损伤与炎症的作用机制[J]. 安徽中医药大学学报, 2024,43(02):73-80.

梁新妹, 王云平, 李丹, 等. Keap1-Nrf2信号通路在机体氧化应激损伤防护中的研究进展[J]. 中国医药导报, 2022,19(35):40-44.

Liu C, Cao J, Zhang H, et al. Evolutionary History of RNA Modifications at N6-Adenosine Originating from the R-M System in Eukaryotes and Prokaryotes[J]. Biology (Basel), 2022,11(2).

Yang Y, Hsu P J, Chen Y S, et al. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism[J]. Cell Res, 2018,28(6):616-624.

罗泰, 黄琼广, 陆战, 等. m6A修饰在肝细胞癌发生发展中的研究进展[J]. 中国癌症防治杂志, 2023,15(04):449-455.

Fan C, Ma Y, Chen S, et al. Comprehensive Analysis of the Transcriptome-Wide m6A Methylation Modification Difference in Liver Fibrosis Mice by High-Throughput m6A Sequencing[J]. Front Cell Dev Biol, 2021,9:767051.

Wang S, Gao S, Ye W, et al. The emerging importance role of m6A modification in liver disease[J]. Biomed Pharmacother, 2023,162:114669.

Liu C, Li X, Gao M, et al. Downregulation of hepatic METTL3 contributes to APAP-induced liver injury in mice[J]. JHEP Rep, 2023,5(8):100766.

Wang P, Xiang M, Zhu L, et al. ALKBH5 Protects Against Hepatic Ischemia-Reperfusion Injury by Regulating YTHDF1-Mediated YAP Expression[J]. Int J Mol Sci, 2024,25(21).

Sun L, Chen X, Zhu S, et al. Decoding m(6)A mRNA methylation by reader proteins in liver diseases[J]. Genes Dis, 2024,11(2):711-726.

Zhang Y, Qi C, Guo Y, et al. Key m(6)A regulators mediated methylation modification pattern and immune infiltration characterization in hepatic ischemia-reperfusion injury[J]. BMC Med Genomics, 2023,16(1):314.

Lv Y, Wu M, Wang Z, et al. Ferroptosis: From regulation of lipid peroxidation to the treatment of diseases[J]. Cell Biol Toxicol, 2023,39(3):827-851.

Zhang L, Luo Y L, Xiang Y, et al. Ferroptosis inhibitors: past, present and future[J]. Front Pharmacol, 2024,15:1407335.

Park E, Chung S W. ROS-mediated autophagy increases intracellular iron levels and ferroptosis by ferritin and transferrin receptor regulation[J]. Cell Death Dis, 2019,10(11):822.

Pan Q, Luo Y, Xia Q, et al. Ferroptosis and Liver Fibrosis[J]. Int J Med Sci, 2021,18(15):3361-3366.

Yang W S, Kim K J, Gaschler M M, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J]. Proc Natl Acad Sci U S A, 2016,113(34):E4966-E4975.

Zhang H L, Hu B X, Li Z L, et al. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation to induce ferroptosis[J]. Nat Cell Biol, 2022,24(1):88-98.

Huang Q, Ru Y, Luo Y, et al. Identification of a targeted ACSL4 inhibitor to treat ferroptosis-related diseases[J]. Sci Adv, 2024,10(13):k1200.

Zhang X D, Liu Z Y, Wang M S, et al. Mechanisms and regulations of ferroptosis[J]. Front Immunol, 2023,14:1269451.

Liu L, Lian N, Shi L, et al. Ferroptosis: Mechanism and connections with cutaneous diseases[J]. Front Cell Dev Biol, 2022,10:1079548.

Jiang X, Stockwell B R, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021,22(4):266-282.

Ursini F, Maiorino M. Lipid peroxidation and ferroptosis: The role of GSH and GPx4[J]. Free Radic Biol Med, 2020,152:175-185.

Zeng L, Liu X, Geng C, et al. Ferroptosis in cancer (Review)[J]. Oncol Lett, 2024,28(1):304.

Dong B, Jiang Y, Shi B, et al. Selenomethionine alleviates decabromodiphenyl ether-induced oxidative stress and ferroptosis via the NRF2/GPX4 pathway in the chicken brain[J]. J Hazard Mater, 2024,465:133307.

郑兰兰, 郭才, 何燕芳, 等. 铁死亡在中药治疗肝纤维化中的研究进展[J]. 中国实验方剂学杂志, 2023,29(23):235-244.

Li L, Zhu Z. Pharmacological modulation of ferroptosis as a therapeutic target for liver fibrosis[J]. Front Pharmacol, 2022,13:1071844.

Deng Y, Lu L, Zhu D, et al. MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells[J]. Cell Death Differ, 2024,31(9):1127-1139.

Liu S. Aryl Hydrocarbon Receptor Alleviates Hepatic Fibrosis by Inducing Hepatic Stellate Cell Ferroptosis[J]. J Cell Mol Med, 2024,28(23):e70278.

Zhang G, Wu K, Jiang X, et al. The role of ferroptosis-related non-coding RNA in liver fibrosis[J]. Front Cell Dev Biol, 2024,12:1517401.

Zhang X, Zhao L, Ying K, et al. TUG1 protects against ferroptosis of hepatic stellate cells by upregulating PDK4-mediated glycolysis[J]. Chem Biol Interact, 2023,383:110673.

Jia K W, Yao R Q, Fan Y W, et al. Interferon-α stimulates DExH-box helicase 58 to prevent hepatocyte ferroptosis[J]. Mil Med Res, 2024,11(1):22.

Li R, Yan X, Xiao C, et al. FTO deficiency in older livers exacerbates ferroptosis during ischaemia/reperfusion injury by upregulating ACSL4 and TFRC[J]. Nat Commun, 2024,15(1):4760.

Meng W, Li L. ZHX2 inhibits diabetes-induced liver injury and ferroptosis by epigenetic silence of YTHDF2[J]. Nutr Diabetes, 2025,15(1):6.

Liu W, He Y, Chen K, et al. YTHDF2 influences hepatic fibrosis by regulating ferroptosis in hepatic stellate cells by mediating the expression of ACSL4 in an m (6)A-dependent manner[J]. Acta Biochim Biophys Sin (Shanghai), 2024,57(4):521-528.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v8i12.34980